Status:
WITHDRAWN
Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Wang Initiative in Lung Cancer Clinical Trials
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with non-small cell lung cancer who are receiving standard treatment with a drug that targets the PD-1 or PD-L1...
Eligibility Criteria
Inclusion
- Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 \>/= 50%)
- Intended treatment with a PD-(L)1 inhibitor
- Age \>/= 18 years
- Karnofsky Performance Status \>/= 70% and medically fit to undergo a biopsy procedure
Exclusion
- Any medical condition or any sites of disease that would preclude a biopsy
- Pregnant or breastfeeding women
- Cognitively impairment affecting ability to understand and provide informed consent
- Prior PD-(L)1 blockade treatment
- Chemotherapy within 6 months prior to enrollment
Key Trial Info
Start Date :
March 8 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 26 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03877250
Start Date
March 8 2019
End Date
August 26 2020
Last Update
May 15 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Memoral Sloan Kettering Basking Ridge (Consent and Follow up)
Basking Ridge, New Jersey, United States, 07920
2
Memoral Sloan Kettering Monmouth (Consent and Follow up)
Middletown, New Jersey, United States, 07748
3
Memorial Sloan Kettering Bergen (Consent and Follow up)
Montvale, New Jersey, United States, 07645
4
Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only)
Commack, New York, United States, 11725